Fig. 1

MICAL2 exhibits high expression levels in cervical cancer cell lines and tumor tissues. A RNA sequencing analysis demonstrates MICAL2 as one of the 59 differential genes between cervical cancer cells and radioresistant cervical cancer cells. B Heatmap reveals that RRSiHa and RRHeLa share 42 significantly upregulated genes, including MICAL2, when compared to their parental Siha and Hela cell lines (n = 3). C Analysis of TCGA pan-cancer data demonstrates MICAL2 expression across various cancer types, with CESC highlighted in red. D WB analysis confirms elevated MICAL2 expression in tumor tissues (T) compared to normal tissues (N) from 16 patients with cervical cancer. E Immunohistochemical (IHC) analysis further demonstrates MICAL2 expression in cancerous and adjacent tissues from 16 patients with cervical cancer, with representative morphograms presented for three cases and quantitative analysis provided for all 16 cases in a histogram. F WB analysis reveals MICAL2 protein expression in one normal cervical cell line and five cervical cancer cell lines (n = 3). Data are presented as mean ± standard deviation, with statistical significance indicated as *p < 0.05, **p < 0.01, and ***p < 0.001 compared to the control group